{"protocolSection":{"identificationModule":{"nctId":"NCT03132571","orgStudyIdInfo":{"id":"1606017928"},"organization":{"fullName":"Yale University","class":"OTHER"},"briefTitle":"Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia","officialTitle":"A Pilot Trial of Naltrexone-Bupropion Combination Versus Placebo Combined With Bupropion for Weight Loss in Comorbid Schizophrenia","acronym":"NBC"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"TERMINATED","whyStopped":"Study discontinued due to funding.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2018-07-31","type":"ACTUAL"},"completionDateStruct":{"date":"2018-07-31","type":"ACTUAL"},"studyFirstSubmitDate":"2017-04-17","studyFirstSubmitQcDate":"2017-04-24","studyFirstPostDateStruct":{"date":"2017-04-28","type":"ACTUAL"},"resultsFirstSubmitDate":"2019-06-28","resultsFirstSubmitQcDate":"2019-08-05","resultsFirstPostDateStruct":{"date":"2019-08-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-08-05","lastUpdatePostDateStruct":{"date":"2019-08-07","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yale University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie reduction diet recommendation for weight and health risk reduction in 40 overweight/obese individuals with schizophrenia.","detailedDescription":"The combination of naltrexone with noradrenaline/dopamine reuptake blocker bupropion has been developed and FDA-approved for the treatment of obesity in the general population. Naltrexone does not normally produce weight loss in humans and bupropion produces modest weight loss, however the combination produces clinically significant weight loss, which appears to be more than the sum of its components would otherwise produce separately. Of interest to us, the combination has been shown to be effective for clinically significant weight loss in obese subjects with type 2 diabetes as well. Registration studies by the manufacturer of the combination pill excluded antipsychotic medication users, thus we have no information on the potential effectiveness of the combination in this population. Both naltrexone and bupropion are commonly used in psychiatry, naltrexone for co-morbid alcohol addiction, and bupropion for co-morbid depression and/or cigarette addiction. This is a 16-week pilot trial of 37.5mg naltrexone/placebo added to extended release bupropion in flexible dosing (150mg to 450mg) and a daily 500 calorie reduction diet recommendation for subjects with schizophrenia and obesity. A dose of 37.5mg is similar to the FDA-approved combination dose for naltrexone. However, based on our experience with bupropion, we have chosen to use bupropion in an un-blinded manner and reach the target dose of 450mg based on tolerance of the individual subject over the initial 3-week period.\n\nChanges to the study since registration:\n\nThe study was initially registered with 3 arms (Naltrexone vs Bupropion vs Placebo)- whereas the original intent was always supposed to be a 2 armed study (Naltrexone vs Placebo- each with Bupropion included)- this was corrected when the results of the terminated study were entered. In addition, there was an initial intent to include diabetics in the study, but this was later removed as well."},"conditionsModule":{"conditions":["Schizophrenia","Diabetes Mellitus, Type 2","Obesity"],"keywords":["Schizophrenia","Diabetes","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Naltrexone versus Placebo assignment will remain double-blinded for the duration of the study; Bupropion dosing will be open-label and not masked to either participant or investigator.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":5,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Naltrexone with Bupropion","type":"EXPERIMENTAL","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.","interventionNames":["Drug: Naltrexone","Drug: Bupropion"]},{"label":"Placebo with Bupropion","type":"PLACEBO_COMPARATOR","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.","interventionNames":["Drug: Bupropion","Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"Naltrexone","description":"37.mg oral capsule taken once daily for over the course of the study (16 weeks)","armGroupLabels":["Naltrexone with Bupropion"],"otherNames":["Revia"]},{"type":"DRUG","name":"Bupropion","description":"Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.","armGroupLabels":["Naltrexone with Bupropion","Placebo with Bupropion"],"otherNames":["Wellbutrin","Zyban"]},{"type":"OTHER","name":"Placebo","description":"Oral placebo taken once daily for the course of the study (16 week)","armGroupLabels":["Placebo with Bupropion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"BMI","description":"BMI will be calculated using weekly height and weight measurements (kg/m\\^2) at each assessment.","timeFrame":"Baseline and Week 16"}],"secondaryOutcomes":[{"measure":"Weight (kg)","description":"Weight in kilograms will be measured at each assessment and change will be determined at study endpoint.","timeFrame":"Baseline and Week 16"},{"measure":"Health Risk Markers","description":"Serum lipid profiles, fasting glucose, and glycosylated hemoglobin (hbA1c) will be measured at baseline and week 16 and change in these markers will be determined at endpoint","timeFrame":"Baseline to Week 16"},{"measure":"Waist Circumference (Inches)","description":"Waist circumference will be measured in inches at each assessment.","timeFrame":"Baseline and Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Age 18 to 75\n2. Meet DSM-IV criteria for schizophrenia or schizoaffective disorder based on SCID interview (If bipolar-schizoaffective: need to be adequately stabilized on a mood stabilizer and show no mania history for the past one year, as confirmed by study psychiatrist and patient's clinician)\n3. Body Mass Index (BMI) of 28 and over\n4. On a stable dose of antipsychotic medication; i.e. at least one month with no dose change, and three months from an antipsychotic switch\n5. Deemed to be symptomatically stable by the clinical staff in the last two months\n6. Over 7% total body weight increase on antipsychotics for subjects within first year of illness\n\nExclusion Criteria\n\n1. Meet criteria for current opiate abuse or dependence (confirmed by positive urine drug screen for opiates or, if suspected by study doctor via patient history and or suspicion of occult opiate use.) Note: All subjects will be screened for drugs, not only those suspected of opiate use.\n2. A history of seizures in the past five years (confirmed through chart review and discussion with patient's clinician)\n3. Meet DSM criteria for Bipolar Disorder\n4. History of mania in the past one year (confirmed through chart review and discussion with patient's clinician)\n5. Uncontrolled hypertension\n6. Insulin dependent diabetes mellitus\n7. Current history of dementia, mental retardation\n8. Not capable of giving informed consent for participation in the study\n9. Women who are pregnant or breast-feeding\n10. Physical conditions affecting body weight (e.g. Cushing's disease, polycystic ovary syndrome)\n11. Severe liver dysfunction, (serum aminotransferases greater than three times normal), acute infectious hepatitis, liver failure.\n12. History of glaucoma.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Cenk Tek, MD","affiliation":"Yale University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Connecticut Mental Health Center","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"30 people were screened by telephone.\n\n18/30 people screened were deemed ineligible. The reasons for ineligibility were: antidepressant medication use (11/18), a history of seizures (4/18) and already taking Naltrexone (3/18).\n\n12/30 people were eligible, 6/12 were initially interested in the study and ultimately, only 5/6 were consented.","groups":[{"id":"FG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"FG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"BG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46.33","spread":"8.14"},{"groupId":"BG001","value":"58.00","spread":"1.41"},{"groupId":"BG002","value":"51.00","spread":"8.63"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"BMI","description":"BMI will be calculated using weekly height and weight measurements (kg/m\\^2) at each assessment.","populationDescription":"Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg/m^2","timeFrame":"Baseline and Week 16","groups":[{"id":"OG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"OG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"39.06","spread":"6.03"},{"groupId":"OG001","value":"29.55","spread":"0.07"}]}]},{"title":"16 Weeks","categories":[{"measurements":[{"groupId":"OG000","value":"37.33","spread":"5.81"},{"groupId":"OG001","value":"30.65","spread":"3.88"}]}]}]},{"type":"SECONDARY","title":"Weight (kg)","description":"Weight in kilograms will be measured at each assessment and change will be determined at study endpoint.","populationDescription":"Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg","timeFrame":"Baseline and Week 16","groups":[{"id":"OG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"OG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"118.78","spread":"11.17"},{"groupId":"OG001","value":"87.25","spread":"15.48"}]}]},{"title":"16 Weeks","categories":[{"measurements":[{"groupId":"OG000","value":"113.60","spread":"11.24"},{"groupId":"OG001","value":"91.25","spread":"27.64"}]}]}]},{"type":"SECONDARY","title":"Health Risk Markers","description":"Serum lipid profiles, fasting glucose, and glycosylated hemoglobin (hbA1c) will be measured at baseline and week 16 and change in these markers will be determined at endpoint","populationDescription":"These labratory data were not collected and summarized due to the removal of diabetes from the study criteria and the early termination of the study.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 16","groups":[{"id":"OG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"OG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Waist Circumference (Inches)","description":"Waist circumference will be measured in inches at each assessment.","populationDescription":"Presented are the baseline and 16 weeks summary data on the 5 patients enrolled.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"inches","timeFrame":"Baseline and Week 16","groups":[{"id":"OG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target."},{"id":"OG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"50.08","spread":"5.26"},{"groupId":"OG001","value":"41.87","spread":"1.23"}]}]},{"title":"16 Weeks","categories":[{"measurements":[{"groupId":"OG000","value":"48.50","spread":"5.76"},{"groupId":"OG001","value":"43.37","spread":"2.29"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events were monitored in patients up to 16 weeks post randomization.","eventGroups":[{"id":"EG000","title":"Naltrexone With Bupropion","description":"Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.\n\nNaltrexone: 37.mg oral capsule taken once daily for over the course of the study (16 weeks)\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":2,"otherNumAtRisk":3},{"id":"EG001","title":"Placebo With Bupropion","description":"Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.\n\nBupropion: Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.\n\nPlacebo: Oral placebo taken once daily for the course of the study (16 week)","deathsNumAffected":0,"deathsNumAtRisk":2,"seriousNumAffected":0,"seriousNumAtRisk":2,"otherNumAffected":0,"otherNumAtRisk":2}],"otherEvents":[{"term":"Nausea","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":3},{"groupId":"EG001","numAffected":0,"numAtRisk":2}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dr. Cenk Tek","organization":"Yale School of Medicine, Department of Psychiatry","email":"cenk.tek@yale.edu","phone":"(203) 974-7500"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-06-13","uploadDate":"2019-08-05T10:06","filename":"Prot_SAP_000.pdf","size":475853}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D012559","term":"Schizophrenia"},{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D009765","term":"Obesity"},{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D019967","term":"Schizophrenia Spectrum and Other Psychotic Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D009271","term":"Naltrexone"},{"id":"D016642","term":"Bupropion"}],"ancestors":[{"id":"D009270","term":"Naloxone"},{"id":"D009019","term":"Morphinans"},{"id":"D053610","term":"Opiate Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006572","term":"Heterocyclic Compounds, Bridged-Ring"},{"id":"D006576","term":"Heterocyclic Compounds, 4 or More Rings"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D010616","term":"Phenanthrenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D011427","term":"Propiophenones"},{"id":"D007659","term":"Ketones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}